Blue Water Vaccines Inc. to Present at H.C. Wainwright Global Investment Conference
May 12 2022 - 8:30AM
Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the
Company”) a biopharmaceutical company developing transformational
vaccines to address significant global health challenges, today
announced that Erin Henderson, Chief Business Officer of Blue Water
Vaccines, will present at the H.C. Wainwright Global Investment
Conference. The presentation will be available for on-demand
webcast viewing starting on Wednesday, May 25, 2022, at 9:00am EDT.
Session details are as follows
Date: |
Wednesday, May 25, 2022 |
Time: |
9:00am Eastern Daylight Time
(EDT) |
Title: |
Blue Water Vaccines Company
Presentation |
BWV
Participant: |
Erin Henderson, Chief Business
Officer |
Webcast
Link: |
https://journey.ct.events/view/1e8775a5-ce07-4395-867a-0cadcc5664e5 |
BWV’s management will be available during the conference for
one-on-one meetings. Interested parties may request a one-on-one
meeting at investors@bluewatervaccines.com or contact BWV
at (513) 620-4101.
About Blue Water Vaccines
Blue Water Vaccines Inc. is a biopharmaceutical company focused
on developing transformational vaccines to address significant
health challenges globally. Headquartered in Cincinnati, OH, the
company holds the rights to proprietary technology developed at the
University of Oxford, Cincinnati Children's Hospital Medical Center
(CCHMC), and St. Jude Children's Hospital. The company is
developing a universal flu vaccine that will provide protection
from all virulent strains in addition to licensing a novel
norovirus (NoV) S&P nanoparticle versatile virus-like particle
(VLP) vaccine platform from CCHMC to develop vaccines for multiple
infectious diseases, including norovirus/rotavirus and malaria,
among others. Additionally, Blue Water Vaccines is developing a
Streptococcus pneumoniae (pneumococcus) vaccine candidate, designed
to specifically prevent the highly infectious middle ear
infections, known as Acute Otitis Media (AOM), in children. For
more information, visit www.bluewatervaccines.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking
within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements may be identified by the use of
forward-looking words such as “anticipate,” “believe,” “forecast,”
“estimate,” “expect,” and “intend,” among others. These
forward-looking statements are based on BWV’s current expectations
and actual results could differ materially. There are a number of
factors that could cause actual events to differ materially from
those indicated by such forward-looking statements. These factors
include, but are not limited to, risks related to the development
of BWV’s vaccine candidates, including, but not limited to BWV-301;
the failure to obtain FDA clearances or approvals and noncompliance
with FDA regulations; delays and uncertainties caused by the global
COVID-19 pandemic; risks related to the timing and progress of
clinical development of our product candidates; our need for
additional financing; uncertainties of patent protection and
litigation; uncertainties of government or third party payor
reimbursement; limited research and development efforts and
dependence upon third parties; and substantial competition. As with
any vaccine under development, there are significant risks in the
development, regulatory approval and commercialization of new
products. BWV does not undertake an obligation to update or revise
any forward-looking statement. Investors should read the risk
factors set forth in BWV’s Annual Report on Form 10-K for the
fiscal year ended December 31, 2021, filed with the Securities and
Exchange Commission (the “SEC”) on March 31, 2022, and periodic
reports filed with the SEC on or after the date thereof. All of
BWV’s forward-looking statements are expressly qualified by all
such risk factors and other cautionary statements. The information
set forth herein speaks only as of the date thereof.
Investor Contact Information:Investor
RelationsEmail: investors@bluewatervaccines.com
Media Contact Information:Media
Relations513-620-4101Email: media@bluewatervaccines.com
Blue Water Biotech (NASDAQ:BWV)
Historical Stock Chart
From Jun 2024 to Jul 2024
Blue Water Biotech (NASDAQ:BWV)
Historical Stock Chart
From Jul 2023 to Jul 2024